Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers

[1]  J. Klijn,et al.  Prophylactic surgery in BRCA1/2 mutation carriers Predictive factors and follow-up , 1999 .

[2]  D. B. Berman,et al.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families , 1996, Nature Medicine.

[3]  S. Narod.  The Cloning of the BRCA1 Gene. , 1996 .

[4]  J. Chamberlain.  Screening for breast cancer in high-risk populations , 1996 .

[5]  C. Deng,et al.  A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability , 1998, Oncogene.

[6]  Steven J Skates,et al.  Screening for ovarian cancer: a pilot randomised controlled trial , 1999, The Lancet.

[7]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[8]  K Offit,et al.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.

[9]  D. Easton,et al.  The contribution of inherited predisposition to cancer incidence. , 1990, Cancer surveys.

[10]  F. Collins,et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.

[11]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[12]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[13]  H. Lynch,et al.  Natural history of colorectal cancer in hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II) , 1988, Diseases of the colon and rectum.

[14]  D. Easton,et al.  Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. , 1995, American journal of human genetics.

[15]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[16]  B. Trock,et al.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. , 1996, JAMA.

[17]  M. Piver,et al.  Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry , 1993, Cancer.

[18]  O. Olopade,et al.  Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2 , 1999, The Lancet.

[19]  D. Clayton,et al.  Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation , 1995, Nature Genetics.

[20]  C. Coleman.  Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2. , 1999, Acta oncologica.

[21]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[22]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[23]  L. Brinton,et al.  Breast implants and cancer. , 1997, Journal of the National Cancer Institute.

[24]  J. Benkendorf,et al.  Bilateral prophylactic mastectomy decision making: A vignette study. , 1999, Preventive medicine.

[25]  M. Skolnick,et al.  A screening study of prostate cancer in high risk families. , 1992, Journal of Urology.

[26]  P. Hartge,et al.  Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[27]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[28]  B. Ponder.  Genetic predisposition to cancer. , 1991, British Journal of Cancer.

[29]  B. Birren,et al.  Campomelic dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9: evidence for an extended control region. , 1999, American journal of human genetics.

[30]  O. Olopade,et al.  Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. , 1998, Journal of the National Cancer Institute.

[31]  J. D. Thompson,et al.  BRCA1 mutations in a population-based sample of young women with breast cancer. , 1996, The New England journal of medicine.

[32]  D. Craufurd,et al.  Predictive testing for Huntington's disease: protocol of the UK Huntington's Prediction Consortium. , 1992, Journal of medical genetics.

[33]  B. Ponder,et al.  Prophylactic oophorectomy in inherited breast/ovarian cancer families. , 1995, Journal of the National Cancer Institute. Monographs.

[34]  C. Larsson,et al.  Mutation analysis of the BRCA2 gene in 49 site–specific breast cancer families , 1996, Nature Genetics.

[35]  T. Powles.  COMMENT ON: TAMOXIFEN FOR PREVENTION OF BREAST CANCER : REPORT OF THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT P-1 STUDY , 1999 .

[36]  J. Struewing,et al.  Population-based study of risk of breast cancer in carriers of BRCA2 mutation , 1998, The Lancet.

[37]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[38]  H. Joensuu,et al.  Mammography screening interval and the frequency of interval cancers in a population-based screening. , 1997, British Journal of Cancer.

[39]  D. Eccles,et al.  Guidelines for a genetic risk based approach to advising women with a family history of breast cancer , 2000, Journal of medical genetics.

[40]  P. Chappuis,et al.  The influence of familial and hereditary factors on the prognosis of breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[42]  R. Collins,et al.  Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.

[43]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[44]  M. Skolnick,et al.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. , 1995, JAMA.

[45]  C. Land,et al.  Incidence of female breast cancer among atomic bomb survivors, 1950-1985. , 1994, Radiation research.

[46]  N Risch,et al.  Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.

[47]  J. Cuzick.  Future possibilities in the prevention of breast cancer: Breast cancer prevention trials , 2000, Breast Cancer Research.

[48]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[49]  L. Bégin,et al.  Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[51]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[52]  Kenneth Offit,et al.  The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% , 1996, Nature Genetics.

[53]  R. Eeles,et al.  Bilateral prophylactic mastectomy: not just a woman's problem! , 1998 .

[54]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[55]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[56]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[58]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[59]  Kenneth Offit,et al.  Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer , 1996, Nature Genetics.

[60]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[61]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[62]  A. Howell,et al.  Screening by mammography, women with a family history of breast cancer. , 1998, European journal of cancer.

[63]  B. Ponder,et al.  Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Cancer research.

[64]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[65]  M. Beckmann,et al.  Utilisation of Prophylactic Mastectomy in 10 European Centres , 2002, Disease markers.

[66]  J. Klijn,et al.  Survival in hereditary breast cancer associated with germline mutations of BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  B. Modan.  BRCA1 mutations and survival in women with ovarian cancer. , 1997, The New England journal of medicine.

[68]  R. Blamey,et al.  Results from a seven-year programme of breast self-examination in 89,010 women. , 1989, British Journal of Cancer.

[69]  S. Cummings,et al.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[71]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[72]  R. Eeles,et al.  BRCA1, BRCA2 and their possible function in DNA damage response , 1999, British Journal of Cancer.

[73]  R. Eeles,et al.  BRCA1/2 carriers and endocrine risk modifiers. , 1999, Endocrine-related cancer.

[74]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[75]  Brown Sl,et al.  Breast Implants and Cancer , 1997 .

[76]  K Offit,et al.  Germline BRCA1 185delAG mutations in Jewish women with breast cancer , 1996, The Lancet.